Stay updated with breaking news from Eric Schoen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AUSTIN, Texas, Nov. 22, 2022 -- Cassava Sciences, Inc. , a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced... | November 22, 2022
Alzheimer’s Patients Who Complete Participation in a Phase 3 Study of Simufilam are Eligible to Enroll52-week Study of Simufilam 100 mgUp to 1,600 Patients...
Cassava Sciences, Inc. SAVA, a clinical-stage biotechnology company focused on Alzheimer's disease, was recently informed by the Journal of Prevention of
SAVA stock is rising on hopes of a buyout, which could also mean optimism for its Alzheimer's test and proposed treatment.
- In November 2021, Cassava Sciences previously disclosed that certain government agencies had asked for corporate information and at that time, the media...